Stalicla Company
Stalicla is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.
Stalicla’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.
Employee Number:
11-50
Headquarters:
Genève, Geneve, Switzerland, Europe
Founded Date:
2017-05-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 22-545-12-42
Investors:
AA Sons, Addex Therapeutics, LIFTT, SPRIM Global Investments
Ipo Status:
private
City:
Genève
Region:
Geneve
Country:
Switzerland
Founders:
Lynn Durham